- Home
- MRSN vs LPA Comparison
MRSN vs LPA Comparison
Compare MRSN & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- LPA
- Stock Information
- Founded
- MRSN 2001
- LPA 2013
- Country
- MRSN United States
- LPA United States
- Employees
- MRSN N/A
- LPA N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- LPA
- Sector
- MRSN Health Care
- LPA
- Exchange
- MRSN Nasdaq
- LPA Nasdaq
- Market Cap
- MRSN 252.0M
- LPA 241.7M
- IPO Year
- MRSN 2017
- LPA N/A
- Fundamental
- Price
- MRSN $0.62
- LPA $10.30
- Analyst Decision
- MRSN Buy
- LPA
- Analyst Count
- MRSN 6
- LPA 0
- Target Price
- MRSN $6.00
- LPA N/A
- AVG Volume (30 Days)
- MRSN 7.3M
- LPA 24.9K
- Earning Date
- MRSN 02-26-2025
- LPA 02-14-2025
- Dividend Yield
- MRSN N/A
- LPA N/A
- EPS Growth
- MRSN N/A
- LPA N/A
- EPS
- MRSN N/A
- LPA N/A
- Revenue
- MRSN $34,837,000.00
- LPA $44,311,428.00
- Revenue This Year
- MRSN N/A
- LPA N/A
- Revenue Next Year
- MRSN N/A
- LPA N/A
- P/E Ratio
- MRSN N/A
- LPA N/A
- Revenue Growth
- MRSN N/A
- LPA 22.46
- 52 Week Low
- MRSN $0.56
- LPA $6.00
- 52 Week High
- MRSN $6.28
- LPA $525.00
- Technical
- Relative Strength Index (RSI)
- MRSN 20.37
- LPA N/A
- Support Level
- MRSN $0.56
- LPA N/A
- Resistance Level
- MRSN $1.45
- LPA N/A
- Average True Range (ATR)
- MRSN 0.14
- LPA 0.00
- MACD
- MRSN -0.06
- LPA 0.00
- Stochastic Oscillator
- MRSN 6.49
- LPA 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.